Yıl: 1999 Cilt: 29 Sayı: 6 Sayfa Aralığı: 683 - 687 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study

Öz:
There are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption. In this study, we have examined urinary Calcium/Creatinine ratio (uCA/Cr) as a biochemical marker of bone turnover to show the effectiveness of etidronate and whether it could be used as a follow-up parameter of treatment. Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial. All necessary criteria matched 81 women were divided into 3 groups at random, each group consisted of 27 patients. Prior to treatment, uCa/Cr was calculated from all subjects 3 hours after drinking 1 liter of water in the morning. Twenty seven (33.3%) women were randomised to oral doses of etidronate (400 mg/day for two weeks followed by drug free period of 10 weeks), twenty seven women to etidronate (400 mg/day for two weeks) plus calcium (1000 mg/day) for the following 10 weeks and twenty seven women to placebo (Fe, 50 mg/day) for 12 weeks. After 12 weeks of treatment, uCa/Cr declined significantly in the etidronate group from 0.118±0.064 to 0.053±0.021, in etidronate+calcium group from 0.08±0.03 to 0.06±0.015 ((p=0.004) and (p=0.005), respectively). In the placebo group no significant change was observed (p=0.03). In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectivensess of etidronate in prevention of osteoporosis. However, since there are contradictory findings concerning uCa/Cr exist, larger clinical and prospective studies should be carried out.
Anahtar Kelime: Urine Etidronate Creatinine Calcium Biological Markers Hormone Replacement Therapy Etidronate Disodium Osteoporosis, Postmenopausal Postmenopause Bone Resorption Estrogen Replacement Therapy

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1. Lindsay R. the menopause and osteoporosis. Obstet Gynecol. (suppl II). 1996; 87: 16S–19S.
  • 2. McGowan JA. Osteoporois: assesment of bone loss and remodeling. Aging Clin Exp Res. 1996; 5: 81–93.
  • 3. Compston JE, Cooper C and Kanis JA. Bone dansitometry in clinical practise. BMJ. 1995; 310: 1507–1510.
  • 4. Reeve J. Future prospects for hormone replacement therapy. Br Med Bull. 1992; 48: 458–468.
  • 5. Christiansen C. The different routes of administration and the effect of hormone replacement therapy on osteoporosis. Fertil Steril. 1994; 62: 152S–156S.
  • 6. Davidson NE. Hormone replacement therapy–breast versus heart versus bone. N Engl J Med. 1995; 332: 1638–39.
  • 7. Body JJ, Pot M, Borkowski A, Sculier JP and Klasterky J. A dose response study of aminohydroyprolidine biphosphonate in tumor–associated hypercalcemia. Am J Med. 1987; 82: 957–63.
  • 8. Averbuch SD. New biphosphonate in the treatment of bone metastases. Cancer. 1993; 72: 3443–52.
  • 9. Singer FR, Minoofar PN. Biphosphonates in the treatment of bone metabolism. Adv Endocrinol Metab. 1995: 6: 259–88.
  • 10. Ott SM. Clinical effects of biphosphonates in involutional osteoporosis. J Bone Miner Res. 1993; 3 (suppl): 597–606.
  • 11. Reginster YJ, Deroisy R, Danis D. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989; ii: 169–1471.
  • 12. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ, Mysiw J, Kohse L, Bhaskar Rao M, Steiger P, Richmond B, Chesnut CH III. Intermittent cyclical eidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1993; 323: 73–76.
  • 13. Storm T, Thamsborg G, Steiniche T, Genant HG, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322: 1265–71, 1990.
  • 14. Rodan GA, Flesch HA. Biphosphonates: mechanism of action. J Clin Invest. 1996; 12: 2692–6.
  • 15. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992; 13: S57–S62.
  • 16. Nordin BEC, Gallagher JC, Aaron JE et al: Postmenopausal osteopenia and osteoporosis. Estrogens in the postmenopause. Front Horm Res 3: 131, 1975.
  • 17. Meunier PJ, Confavreux E, Tupinon I, Hardoim C, Delmas PD and Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (A double–blind, placebo–controlled study and 1–year follow–up). J Clin Endocrinol. Metab. 1997; 82: 2784–91.
  • 18. Heilberg IP, Martini LA, Teixeira SH, Szejnfeld VL, Cavalho AB, Labao R and Draibe SA. Effect of etidronate treatment on bone mass of male Nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron. 1998; 79: 430–437.
  • 19. Diamond T, Campell J, Bryant C and Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998; 83: 1561–6.
  • 20. Storm, T, Steiniche T, Thamsborg G, Melsen F: Changes in bone histomorphometry after long–term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J. Bone Miner. Res. 8 (2) 199–208, 1993.
  • 21. Smith M.L., Fogelman I, Hart DM, Scott E, Bevan J, Leggate I; Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int. 44 (2) 74–9, 1989.
  • 22. Reitsma Ph, Bijvoet OLM, Verlinden–Ooms H, van der Wee–Pals L. Kinetic studies of bone and mineral metabolism during treatment with (3–amino–l–hydroxypropylidene) –1, 1–bisphosphonate (APD) in rats. Calcif. Tissue Int. 2: 45–57, 1980.
  • 23. Canfield RE. Rationale for diphosphonate therapy in hypercalcemia of malignancy. Am. J. Ed. 1987; 82: 2A: 1–78.
  • 24. Kanis JA. Clodronate– A new perspective in the treatment of neoplastic bone disease. Bone, 1987; 8: 1.
  • 25. Harinck HIJ: Bijvoet OLM; Plantingh AST; Body J; Elte JWF; Sleebom HP et al. The role of bone and kidney in tumor hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am. J. Med. 82: 1133–42, 1987.
  • 26. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, and Chesnut II CH. The effect of short term treatment with alendronate on vertabral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993; 76: 1399–1406.
  • 27. Reasner CA, Stone MD, Hosking DJ, Ballah A and Mundy GR. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocr Metab. 1993; 77: 1067–71.
  • 28. Sairanen S, Tahtela R, Laitinen K, Löyttyniemi E and Valimaki MJ. Effects of short–term treatment with clodronate on parameters of bone metabolism and their diurnal variation. Calcif Tissue Int. 1997; 60: 160–163.
  • 29. Body JJ, Dumon JC, Gineyts E. and Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer–iduced osteolysis before and after biophosphonate therapy. Br J Cancer. 1997; 75(3): 408–412.
  • 30. Ravn P, Clemmesen B, RIIS BJ and Christiansen C. The effect of bone mass and bone markers of different doses of ibandronate: A new biphosphonate for prevention and treatment of postmenopasal osteoporosis: A 1–year, randomised, double–blind, placebo controlled dose–finding study. Bone. 1996; 19: 527–533.
APA KÜÇÜK Ş, GÖKDENİZ R, ATMACA R, URYAN İ, BUHUR A, TAŞKIN Ö (1999). Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. , 683 - 687.
Chicago KÜÇÜK Şenol,GÖKDENİZ Remzi,ATMACA Ruşen,URYAN İsmail,BUHUR Ali,TAŞKIN Ömür Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. (1999): 683 - 687.
MLA KÜÇÜK Şenol,GÖKDENİZ Remzi,ATMACA Ruşen,URYAN İsmail,BUHUR Ali,TAŞKIN Ömür Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. , 1999, ss.683 - 687.
AMA KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. . 1999; 683 - 687.
Vancouver KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. . 1999; 683 - 687.
IEEE KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö "Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study." , ss.683 - 687, 1999.
ISNAD KÜÇÜK, Şenol vd. "Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study". (1999), 683-687.
APA KÜÇÜK Ş, GÖKDENİZ R, ATMACA R, URYAN İ, BUHUR A, TAŞKIN Ö (1999). Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences, 29(6), 683 - 687.
Chicago KÜÇÜK Şenol,GÖKDENİZ Remzi,ATMACA Ruşen,URYAN İsmail,BUHUR Ali,TAŞKIN Ömür Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences 29, no.6 (1999): 683 - 687.
MLA KÜÇÜK Şenol,GÖKDENİZ Remzi,ATMACA Ruşen,URYAN İsmail,BUHUR Ali,TAŞKIN Ömür Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences, vol.29, no.6, 1999, ss.683 - 687.
AMA KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences. 1999; 29(6): 683 - 687.
Vancouver KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences. 1999; 29(6): 683 - 687.
IEEE KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö "Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study." Turkish Journal of Medical Sciences, 29, ss.683 - 687, 1999.
ISNAD KÜÇÜK, Şenol vd. "Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study". Turkish Journal of Medical Sciences 29/6 (1999), 683-687.